Enzyme replacement therapy in α-mannosidosis guinea-pigs

Allison C. Crawley, Barbara King, Thomas Berg, Peter J. Meikle, John J. Hopwood

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

α-Mannosidosis is a lysosomal storage disorder caused by deficient activity of lysosomal α-mannosidase and is characterised by massive accumulation of mannose-containing oligosaccharides in affected individuals. Patients develop behaviour and learning difficulties, skeletal abnormalities, immune deficiency and hearing impairment. Disease in α-mannosidosis guinea-pigs resembles the clinical, histopathological, biochemical and molecular features of the human disease. We have used the guinea-pig model to investigate efficacy of enzyme replacement therapy as a treatment for α-mannosidosis. Intravenous recombinant human lysosomal α-mannosidase, administered at a dose of 1 mg/kg, was cleared from circulation with a half-life of 53 h, with significant enzyme activity (1.4× normal levels) detected in circulation one week post-injection. α-Mannosidase administered to α-mannosidosis guinea-pigs at 1 mg/kg (onset at birth or ∼30 days) and 10 mg/kg (at birth) was distributed widely amongst tissues, including to capillary depleted brain. By monitoring with tandem mass spectrometry, enzyme replacement therapy was found to be effective in reducing stored substrates in peripheral tissues at both dose rates, and in brain by up to 39% at the 10 mg/kg dose, compared with untreated α-mannosidosis controls. Reductions of up to 60% of urinary mannose containing oligosaccharides were also observed. No histological improvements were seen in the brain at either dose, however marked decreases in lysosomal vacuolation in liver, kidney, spleen and endocrine pancreas, as well as a significant reduction in trigeminal ganglion neurons were observed. Multiple injections of 1 mg/kg recombinant enzyme in α-mannosidosis guinea-pigs induced a very rapid humoral immune response precluding long-term intravenous treatment.

LanguageEnglish
Pages48-57
Number of pages10
JournalMolecular Genetics and Metabolism
Volume89
Issue number1-2
DOIs
Publication statusPublished - 1 Sep 2006

Keywords

  • Animal model
  • Enzyme replacement
  • Genetic disease
  • Guinea-pig
  • Lysosomal storage disease
  • Therapy
  • α-Mannosidase

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Crawley, A. C., King, B., Berg, T., Meikle, P. J., & Hopwood, J. J. (2006). Enzyme replacement therapy in α-mannosidosis guinea-pigs. Molecular Genetics and Metabolism, 89(1-2), 48-57. https://doi.org/10.1016/j.ymgme.2006.05.005
Crawley, Allison C. ; King, Barbara ; Berg, Thomas ; Meikle, Peter J. ; Hopwood, John J. / Enzyme replacement therapy in α-mannosidosis guinea-pigs. In: Molecular Genetics and Metabolism. 2006 ; Vol. 89, No. 1-2. pp. 48-57.
@article{1b522119d21b47f2a805e36ffba8b7bd,
title = "Enzyme replacement therapy in α-mannosidosis guinea-pigs",
abstract = "α-Mannosidosis is a lysosomal storage disorder caused by deficient activity of lysosomal α-mannosidase and is characterised by massive accumulation of mannose-containing oligosaccharides in affected individuals. Patients develop behaviour and learning difficulties, skeletal abnormalities, immune deficiency and hearing impairment. Disease in α-mannosidosis guinea-pigs resembles the clinical, histopathological, biochemical and molecular features of the human disease. We have used the guinea-pig model to investigate efficacy of enzyme replacement therapy as a treatment for α-mannosidosis. Intravenous recombinant human lysosomal α-mannosidase, administered at a dose of 1 mg/kg, was cleared from circulation with a half-life of 53 h, with significant enzyme activity (1.4× normal levels) detected in circulation one week post-injection. α-Mannosidase administered to α-mannosidosis guinea-pigs at 1 mg/kg (onset at birth or ∼30 days) and 10 mg/kg (at birth) was distributed widely amongst tissues, including to capillary depleted brain. By monitoring with tandem mass spectrometry, enzyme replacement therapy was found to be effective in reducing stored substrates in peripheral tissues at both dose rates, and in brain by up to 39{\%} at the 10 mg/kg dose, compared with untreated α-mannosidosis controls. Reductions of up to 60{\%} of urinary mannose containing oligosaccharides were also observed. No histological improvements were seen in the brain at either dose, however marked decreases in lysosomal vacuolation in liver, kidney, spleen and endocrine pancreas, as well as a significant reduction in trigeminal ganglion neurons were observed. Multiple injections of 1 mg/kg recombinant enzyme in α-mannosidosis guinea-pigs induced a very rapid humoral immune response precluding long-term intravenous treatment.",
keywords = "Animal model, Enzyme replacement, Genetic disease, Guinea-pig, Lysosomal storage disease, Therapy, α-Mannosidase",
author = "Crawley, {Allison C.} and Barbara King and Thomas Berg and Meikle, {Peter J.} and Hopwood, {John J.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.ymgme.2006.05.005",
language = "English",
volume = "89",
pages = "48--57",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

Crawley, AC, King, B, Berg, T, Meikle, PJ & Hopwood, JJ 2006, 'Enzyme replacement therapy in α-mannosidosis guinea-pigs', Molecular Genetics and Metabolism, vol. 89, no. 1-2, pp. 48-57. https://doi.org/10.1016/j.ymgme.2006.05.005

Enzyme replacement therapy in α-mannosidosis guinea-pigs. / Crawley, Allison C.; King, Barbara; Berg, Thomas; Meikle, Peter J.; Hopwood, John J.

In: Molecular Genetics and Metabolism, Vol. 89, No. 1-2, 01.09.2006, p. 48-57.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enzyme replacement therapy in α-mannosidosis guinea-pigs

AU - Crawley, Allison C.

AU - King, Barbara

AU - Berg, Thomas

AU - Meikle, Peter J.

AU - Hopwood, John J.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - α-Mannosidosis is a lysosomal storage disorder caused by deficient activity of lysosomal α-mannosidase and is characterised by massive accumulation of mannose-containing oligosaccharides in affected individuals. Patients develop behaviour and learning difficulties, skeletal abnormalities, immune deficiency and hearing impairment. Disease in α-mannosidosis guinea-pigs resembles the clinical, histopathological, biochemical and molecular features of the human disease. We have used the guinea-pig model to investigate efficacy of enzyme replacement therapy as a treatment for α-mannosidosis. Intravenous recombinant human lysosomal α-mannosidase, administered at a dose of 1 mg/kg, was cleared from circulation with a half-life of 53 h, with significant enzyme activity (1.4× normal levels) detected in circulation one week post-injection. α-Mannosidase administered to α-mannosidosis guinea-pigs at 1 mg/kg (onset at birth or ∼30 days) and 10 mg/kg (at birth) was distributed widely amongst tissues, including to capillary depleted brain. By monitoring with tandem mass spectrometry, enzyme replacement therapy was found to be effective in reducing stored substrates in peripheral tissues at both dose rates, and in brain by up to 39% at the 10 mg/kg dose, compared with untreated α-mannosidosis controls. Reductions of up to 60% of urinary mannose containing oligosaccharides were also observed. No histological improvements were seen in the brain at either dose, however marked decreases in lysosomal vacuolation in liver, kidney, spleen and endocrine pancreas, as well as a significant reduction in trigeminal ganglion neurons were observed. Multiple injections of 1 mg/kg recombinant enzyme in α-mannosidosis guinea-pigs induced a very rapid humoral immune response precluding long-term intravenous treatment.

AB - α-Mannosidosis is a lysosomal storage disorder caused by deficient activity of lysosomal α-mannosidase and is characterised by massive accumulation of mannose-containing oligosaccharides in affected individuals. Patients develop behaviour and learning difficulties, skeletal abnormalities, immune deficiency and hearing impairment. Disease in α-mannosidosis guinea-pigs resembles the clinical, histopathological, biochemical and molecular features of the human disease. We have used the guinea-pig model to investigate efficacy of enzyme replacement therapy as a treatment for α-mannosidosis. Intravenous recombinant human lysosomal α-mannosidase, administered at a dose of 1 mg/kg, was cleared from circulation with a half-life of 53 h, with significant enzyme activity (1.4× normal levels) detected in circulation one week post-injection. α-Mannosidase administered to α-mannosidosis guinea-pigs at 1 mg/kg (onset at birth or ∼30 days) and 10 mg/kg (at birth) was distributed widely amongst tissues, including to capillary depleted brain. By monitoring with tandem mass spectrometry, enzyme replacement therapy was found to be effective in reducing stored substrates in peripheral tissues at both dose rates, and in brain by up to 39% at the 10 mg/kg dose, compared with untreated α-mannosidosis controls. Reductions of up to 60% of urinary mannose containing oligosaccharides were also observed. No histological improvements were seen in the brain at either dose, however marked decreases in lysosomal vacuolation in liver, kidney, spleen and endocrine pancreas, as well as a significant reduction in trigeminal ganglion neurons were observed. Multiple injections of 1 mg/kg recombinant enzyme in α-mannosidosis guinea-pigs induced a very rapid humoral immune response precluding long-term intravenous treatment.

KW - Animal model

KW - Enzyme replacement

KW - Genetic disease

KW - Guinea-pig

KW - Lysosomal storage disease

KW - Therapy

KW - α-Mannosidase

UR - http://www.scopus.com/inward/record.url?scp=33747008880&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2006.05.005

DO - 10.1016/j.ymgme.2006.05.005

M3 - Article

VL - 89

SP - 48

EP - 57

JO - Molecular Genetics and Metabolism

T2 - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -